These results provide insights regarding the function of Gbb/TGF-β signaling in metabolic disease, and suggest that this pathway represents a promising therapeutic target for treatment of obesity and diabetes. Here, TGFB1 is linked to obesity due to melanocortin 4 receptor deficiency.